Our Products

AGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)

TARDOXAL™ - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet need

About Medicure

Medicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.

History

Medicure founded in 1997 is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure has raised over $140 million and focused this investment on the advancement and clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to AGGRASTAT (tirofiban HCl), a cardiovascular drug originally developed by Merck. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome. Medicure's business is generating revenue to support operations and to make selected investments in the clinical advancement of AGGRASTAT.

Today

Medicure's core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT. The Company has an experienced commercial team dedicated exclusively to the marketing of AGGRASTAT. The drug is experiencing renewed interest from hospitals and clinicians in the US due to its compelling clinical and economic evidence.

Aggrastat is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). For additional information and full Prescribing Information, health care professionals can visit the AGGRASTAT product website.

The US rights to Aggrastat are owned by Medicure's subsidiary, Medicure International, Inc. (Barbados) and the product is distributed in the United States by Medicure's US subsidiary, Medicure Pharma, Inc.

Medicure opportunistically looks at small molecule development opportunities and currently has development programs in the neurology and cardiology fields.



For more information on the Company and the risks and uncertainties involved in its business, please refer to the most recent Management Discussion and Analysis, as provided on a quarterly basis, and in the "Risk Factors" section of its most recent Form 20F. The Company's ability to continue in operation for the foreseeable future remains dependent upon the effective execution of its business development and strategic plans.